Hugel Inc 2022 AR2
The report highlights Hugel's financial and ESG performance for the fiscal year 2022, achieving a record consolidated revenue of KRW 281.7 billion. The company expanded its global footprint by launching its botulinum toxin product, Letybo, in Europe and securing marketing approvals in Canada and Australia. On the environmental front, Hugel enhanced energy efficiency through LED installations and operated a 90kWh solar power system. Socially, the company was recognized as a Family-friendly Company, increased female employment to 45.4%, and actively engaged in local community contributions, including donating charcoal briquettes and derma cosmetics.
Company: Hugel Inc
Sector: Health Care
Country: South Korea
Year: 2022
Type: AR2
Pages: 63
Hugel Inc
Annual Report
The report highlights Hugel's financial and ESG performance for the fiscal year 2022, achieving a record consolidated revenue of KRW 281.7 billion. The company expanded its global footprint by launching its botulinum toxin product, Letybo, in Europe and securing marketing approvals in Canada and Australia. On the environmental front, Hugel enhanced energy efficiency through LED installations and operated a 90kWh solar power system. Socially, the company was recognized as a Family-friendly Company, increased female employment to 45.4%, and actively engaged in local community contributions, including donating charcoal briquettes and derma cosmetics.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Employees